Search Results - zhiya+yu

7 Results

Sort By:

T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools

Tumor-specific mutated proteins can create neoepitopes, mutation-derived antigens that distinguish tumor cells from healthy cells, which are attractive targets for adoptive cell therapies. However, the process of precisely identifying the neoepitopes to target is complex and challenging. One method to identify such neoepitopes is Mass Spectrometry (MS)...

Published: 4/8/2024 | Inventor(s): Catherine Ade, Matthew Sporn, Zhiya Yu

Keywords(s):

Category(s): Application > Research Materials, Application > Diagnostics, Collaboration Sought > Licensing, TherapeuticArea > Oncology

T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use

Summary: The National Cancer Institute (NCI) has identified HLA-A11:01-restricted T Cell Receptors (TCRs) targeting the KRAS G13D mutation. The NCI seeks licensees for the use of these TCRs in research. Description of Technology: Tumor-specific mutated proteins can create immunogenic, mutation-containing “neoepitopes” which are attractive...

Published: 4/8/2024 | Inventor(s): Catherine Ade, Zhiya Yu, Matthew Sporn, James Yang, Kenichi Hanada

Keywords(s):

Category(s): TherapeuticArea, Application, Application > Research Materials, Collaboration Sought > Licensing

Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer

Abstract: Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes autologous, antitumor T cells to attack tumors through recognition of tumor-specific mutations, or neoantigens. A major hurdle in the development of ACT is the exhausted phenotype exhibited by many neoantigen-specific T cells, which limits their efficacy...

Published: 4/8/2024 | Inventor(s): Sri Krishna, Zhiya Yu, Kenichi Hanada, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Krishna, Neoantigen, Rosenberg, T-Cell Receptor, TCR, Vaccine

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Novel Murine T-Cell Receptors for Treating Metastatic Thyroid Cancer

Abstract: The occurrence of thyroid cancer has been increasing in the United States. For some patients, with particularly advanced and metastatic cancer, current treatments such as thyroidectomy and adjuvant radioactive iodine therapy can lead to poor outcomes. Hence, there is a need for new thyroid cancer treatments. Researchers at the NCI have developed...

Published: 4/8/2024 | Inventor(s): Kenichi Hanada, Qiong Wang, James Yang, Zhiya Yu

Keywords(s): act, adoptive cell therapy, Human Thyroglobulin, Immunotherapy, METASTATIC, T-cell Receptors, TCR, TCRs, Tg, THYROID CANCER, Yang

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration

T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy

Abstract: BRAF is an oncogene that encodinges a serine-threonine kinase (B-Raf kinase) important in regulating cell growth and differentiation. Spontaneous mutations in the BRAF gene allow cells to continuously divide, leading to the development of cancer. A substitution of glutamic acid for valine at amino acid number 600 (designated V600E) accounts...

Published: 8/14/2024 | Inventor(s): Zhiya Yu, Catherine Ade, Matthew Sporn, James Yang, Kenichi Hanada

Keywords(s): BRAF, B-Raf kinase, B-Raf Proto-Oncogene, HLA-A*0301 restriction, Immunotherapy, Rosenberg, serine-threonine kinase, T Cell Receptor, T cell therapy, TCR, V600E mutation, Yang, Yu

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Novel Immunotherapy for Cancer Treatment: Chimeric Antigen Receptors Targeting CD70 Antigen

Abstract: Scientists at the NCI's Surgery Branch have developed anti-CD70 chimeric antigen receptors (CARs) to treat cancers. CD70 is an antigen that is expressed on a variety of human cancers such as renal cell carcinoma, glioblastoma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. The anti-CD70 CARs are hybrid proteins consisting of a receptor...

Published: 4/8/2024 | Inventor(s): Qiong Wang, Zhiya Yu, James Yang

Keywords(s): CARS, CD70, chimeric antigen receptor, T-cell reprogramming

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

Novel Cancer Immunotherapy: A T Cell Receptor That Specifically Recognizes Common KRAS Mutations

Abstract: Several malignancies associated with a poor prognosis such as lung, pancreatic and colorectal cancers frequently harbor constitutively active KRAS mutants, which play a pivotal role in oncogenesis. Currently, there are no potentially curative treatments against most mutant KRAS harboring cancers once they become metastatic and unresectable. ...

Published: 4/8/2024 | Inventor(s): Qiong Wang, James Yang, Zhiya Yu

Keywords(s): Colorectal, Immunotherapy, KRAS, LUNG, oncogenesis, PANCREAS, PROSTATE, T cell, TCR

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics